Evidence map›Paper›PMID 29095427›Full record

ArticleClinical and translational gastroenterology2017

Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study.

Liset Westera, Tanja van Viegen, Jenny Jeyarajah, Azar Azad, Janine Bilsborough, Gijs R van den Brink, Jonathan Cremer, Silvio Danese, Geert D'Haens, Lars Eckmann and 18 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 10 institutions in 6 countries.

Liset WesteraTytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands.
Tanja van ViegenRobarts Clinical Trials, BV., Amsterdam, Netherlands.
Jenny JeyarajahRobarts Clinical Trials, London, Ontario, Canada.
Azar AzadMount Sinai Services, Toronto, Ontario, Canada.
Janine BilsboroughF. Widjaja Foundation Inflammatory Bowel and Immunobiology Institute, Los Angeles, CA, USA.
Gijs R van den BrinkTytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands.
Jonathan CremerUniversity of Leuven, Leuven, Belgium.
Silvio DaneseHumanitas University, Milan, Italy.
Geert D'HaensRobarts Clinical Trials, BV., Amsterdam, Netherlands.
Lars EckmannDivision of Gastroenterology, School of Medicine, University of California San Diego, San Diego, CA, USA.
William FaubionMayo Clinic, Rochester, MN, USA.
Melissa FiliceMount Sinai Hospital, Toronto, Ontario, Canada.
Hannelie KorfUniversity of Leuven, Leuven, Belgium.
Dermot McGovernF. Widjaja Foundation Inflammatory Bowel and Immunobiology Institute, Los Angeles, CA, USA.
Julian PanesInstitut d'Investigacions Biomèdiques August Pi i Sunyer- Hospital Clínic Barcelona, Barcelona, Spain.
Azucena SalasInstitut d'Investigacions Biomèdiques August Pi i Sunyer- Hospital Clínic Barcelona, Barcelona, Spain.
William J SandbornDivision of Gastroenterology, School of Medicine, University of California San Diego, San Diego, CA, USA.
Mark S SilverbergMount Sinai Hospital, Toronto, Ontario, Canada.
Michelle I SmithMount Sinai Hospital, Toronto, Ontario, Canada.
Severine VermeireUniversity of Leuven, Leuven, Belgium.
Stefania VetranoHumanitas University, Milan, Italy.
Lisa M ShackeltonRobarts Clinical Trials, London, Ontario, Canada.
Larry StittRobarts Clinical Trials, London, Ontario, Canada.
Vipul JairathRobarts Clinical Trials, London, Ontario, Canada.
Barrett G LevesqueDivision of Gastroenterology, School of Medicine, University of California San Diego, San Diego, CA, USA.
David M SpencerRobarts Clinical Trials, San Diego, CA, USA.
Brian G FeaganRobarts Clinical Trials, London, Ontario, Canada.
Niels Vande CasteeleDivision of Gastroenterology, School of Medicine, University of California San Diego, San Diego, CA, USA.
Robarts Clinical Trials · CAKU Leuven · BEMount Sinai Hospital · CAConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHumanitas University · ITLos Angeles Clinical Trials · USUniversity of California, San Diego · USAcademic Medical Center · NLMayo Clinic in Arizona · USSinai Health System · CA

Funding

Using polygenic scores to enhance both variant discovery, and understanding of functional consequences of genetic variation in IBD.P01DK046763 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI TARGAN, STEPHAN R. · 1992 to 2020
$31.1M
NIDDK NIH HHS P01 DK046763
6 · The paper itself

Abstract

objectivesFlow cytometry (FC) aids in characterization of cellular and molecular factors involved in pathologic immune responses. Although FC has potential to facilitate early drug development in inflammatory bowel disease, interlaboratory variability limits its use in multicenter trials. Standardization of methods may address this limitation. We compared variability in FC-aided quantitation of T-cell responses across international laboratories using three analytical strategies.

methodsPeripheral blood mononuclear cells (PBMCs) were isolated from three healthy donors, stimulated with phorbol 12-myristate 13-acetate and ionomycin at a central laboratory, fixed, frozen, and shipped to seven international laboratories. Permeabilization and staining was performed in triplicate at each laboratory using a common protocol and centrally provided reagents. Gating was performed using local gating with a local strategy (LGLS), local gating with a central strategy (LGCS), and central gating (CG). Median cell percentages were calculated across triplicates and donors, and reported for each condition and strategy. The coefficient of variation (CV) was calculated across laboratories. Between-strategy comparisons were made using a two-way analysis of variance adjusting for donor.

resultsMean interlaboratory CV ranged from 1.8 to 102.1% depending on cell population and gating strategy (LGLS, 4.4-102.1%; LGCS, 10.9-65.6%; CG, 1.8-20.9%). Mean interlaboratory CV differed significantly across strategies and was consistently lower with CG.

conclusionsCentral gating was the only strategy with mean CVs consistently lower than 25%, which is a proposed standard for pharmacodynamic and exploratory biomarker assays.

Identifiers

PMID29095427
PMCPMC5717516
OpenAlexW2766399993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.